Editorial: Viral vector-based gene therapy in neurological disease: The future is now

Jared B Smith; Laura Cancedda; Sergiusz Jozwiak; Andrew C Mercer

doi:10.3389/fneur.2023.1153681

Editorial: Viral vector-based gene therapy in neurological disease: The future is now

Front Neurol. 2023 Feb 14:14:1153681. doi: 10.3389/fneur.2023.1153681. eCollection 2023.

Authors

Jared B Smith¹, Laura Cancedda², Sergiusz Jozwiak³, Andrew C Mercer¹

Affiliations

¹ Research and Early Development, REGENXBIO Inc., Rockville, MD, United States.
² Brain Development and Disorders Lab, Istituto Italiano di Tecnologia, Genoa, Italy.
³ Research Department, The Children's Memorial Health Institute (IPCZD), Warsaw, Poland.

No abstract available

Keywords: adeno-associated virus (AAV); antibody; gene replacement; gene therapy; promoter; spinal muscular atrophy (SMA); viral vector.

Publication types

Editorial

Grants and funding

This work was funded by European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Program (Grant Agreement No. 725563 to LC).